Pfizer is in discussion with government to sell its promising covid-19 vaccine in India, and believes its candidate has the potential to be an important part of India’s early vaccine response, a spokesperson for Pfizer India said in a statement.
Volunteers of the experimental vaccine candidate of Pfizer said they experienced "severe" hangover, headache and pain after receiving the first shot of the vaccine.
Covid-19 vaccine, Covaxin, being developed by Bharat Biotech is now undergoing phase-3 trials, Krishna Ella, Chairman and Managing Director, Bharat Biotech said on Monday.
Pfizer has previously said it expects to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November, meaning the announcement could be days away.